Pharmacogenetic test expanded, 20 genes

• Clopidogrel resistance (risk of recurrent strokes and heart attacks): detects mutations (e.g., in the CYP2C19 gene) that prevent the body from activating this antiplatelet drug. This poses a risk of stent thrombosis after stenting.
• Warfarin intoxication: detects defects in the CYP2C9 and VKORC1 genes that slow warfarin clearance, leading to critical blood thinning and severe internal bleeding.
• Statin-induced myopathy and rhabdomyolysis: detects abnormalities in the SLCO1B1 transporter gene, causing statins to accumulate in muscles, resulting in severe pain, muscle tissue breakdown (rhabdomyolysis), and kidney damage.

• Pharmacoresistant depression: detects abnormally fast or slow metabolism of antidepressants due to defects in CYP2D6 and CYP2C19 genes. This explains why standard drug doses are ineffective or cause severe psychosis and anxiety.
• Ineffectiveness of anticonvulsant and antiparkinsonian therapy: identifies genetic causes for lack of response to epilepsy or Parkinson’s disease treatment, leading to frequent relapses and seizures.
• Severe extrapyramidal symptoms: detects risk of movement disorders (tremor, dystonia) when taking neuroleptics.

• Critical toxicity of fluoropyrimidines (5-fluorouracil, capecitabine): detects deficiency of the DPD enzyme (DPYD gene). Such deficiency makes chemotherapy lethally toxic, causing profound bone marrow suppression and sepsis.
• Neurotoxicity and myelosuppression: identifies genetic predisposition to severe nervous system and blood damage from other chemotherapy drugs.
• Ineffectiveness of ulcer and GERD therapy: detects "ultra-rapid metabolizers" of proton pump inhibitors (omeprazole, etc.), in whom the drugs are broken down instantly, failing to reduce stomach acidity.

• Stevens-Johnson syndrome and toxic epidermal necrolysis: the test analyzes the HLA antigen system (e.g., HLA-B). The presence of certain alleles when taking some drugs (carbamazepine, allopurinol) triggers life-threatening allergic reactions with skin detachment and internal organ damage.

• The need for long-term or lifelong medication use (chronic cardiovascular diseases, psychiatric and neurological disorders, endocrine disorders).
• Use of drugs with a narrow therapeutic index: medications where the minimum effective dose is very close to the toxic dose (warfarin, cytostatics, immunosuppressants, etc.).
• High risk of severe adverse reactions: presence in the patient or family history of severe complications or intoxication during standard medication doses.
• Resistance or ineffectiveness of standard therapy: when prolonged use of drugs at standard doses does not produce the expected clinical effect, requiring precise dose adjustment or replacement with an alternative drug with a different metabolism pathway.
• Polypharmacy (simultaneous use of multiple drugs): assessment of drug compatibility and prediction of interaction risks considering genetically determined enzyme activity rates.
• Personalized therapy selection "in advance": testing before treatment to immediately prescribe an effective regimen and avoid trial-and-error methods.

Molecular genetic genotyping (Illumina sequencing technology).

• Do not eat, drink, smoke, brush teeth, or chew gum for 1 hour before saliva collection.
• Collect saliva according to the instructions included in the kit.